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Nine month follow-up of amlodipine maleate
and amlodipine besylate treatment in patients
with essential hypertension: does the salt
form matter?
Ocena i porównanie skuteczności hipotensyjnej i tolerancji maleinianu amlodypiny
i benzenosulfonianu amlodypiny u chorych z nadciśnieniem tętniczym pierwotnym
Streszczenie
Wstęp Celem przeprowadzonego, wieloośrodkowe-
go, trwającego sześć miesięcy badania była ocena
skuteczności hipotensyjnej i tolerancji maleinianu
amlodypiny u chorych na nadciśnienie tętnicze.
Materiał i metody W pierwszej części badania po-
równano skuteczność hipotensyjną maleinianu amlo-
dypiny (Tenox, Krka) i benzenosulfonianu amlody-
piny (Norvasc, Pfizer) w trwającym trzy miesiące ba-
daniu przeprowadzonym metodą podwójnie ślepej
próby w grupach równoległych. W drugiej części ba-
dania oceniano skuteczność hipotensyjną i tolerancję
maleinianu amlodypiny w trwającym sześć miesięcy
badaniu przeprowadzonym metodą otwartą. Bada-
niem objęto 245 chorych (w pierwszej części)
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i 202 chorych (w drugiej części) z nadciśnieniem tętni-
czym zdefiniowanym jako rozkurczowe ciśnienie tętni-
cze 95–114 mm Hg. Kryterium skuteczności leczenia
było obniżenie ciśnienia rozkurczowego do wartości
89 mm Hg i mniej lub obniżenie ciśnienia rozkurczowe-
go o 10 mm Hg i więcej. Do drugiej części badania
włączono chorych u których uzyskano zadawalającą
kontrolę ciśnienia tętniczego w pierwszej części.
Wyniki W trakcie pierwszej części badania leczenie
obydwoma lekami było związane z istotnym, porów-
nywalnym obniżeniem ciśnienia tętniczego. Lecze-
nie benzenosulfonianem amlodypiny związane było
z większym obniżeniem rozkurczowego ciśnienia
tętniczego o 1,27 mm Hg w porównaniu z lecze-
niem maleinianem amlodypiny (różnica ta była jed-
nak nieistotna stastycznie i mieściła się w 90% prze-
dziale ufności braku różnic pomiędzy porównywa-
nymi lekami). Nie zaobserwowano różnic pomiędzy
chorymi leczonymi badanymi solami amlodypiny
w odniesieniu do częstości osiągnięcia docelowych
wartości rozkurczowego ciśnienia tętniczego(90,91%
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i 89,52% odpowiednio dla maleinianu i benzenosul-
fonianu amlodypiny). W drugiej części badania, po
6 miesiącach, leczenie maleinianem amlodypiny
związane było z obniżeniem rozkurczowego i skur-
czowego ciśnienia tętniczego o –17,5/–21,2 mm Hg
w porównaniu z wartościami wyjściowymi. W trak-
cie pierwszej części badania u 35 chorych w grupie
otrzymującej maleinian amlodypiny i 47 chorych
w grupie otrzymującej benzenosulfonian amlodypiny
wystąpiły zdarzenia niepożądane (28,9% vs. 37,9%,
p = NS). Częstość występowania zdarzeń niepożą-
danych w drugiej części badania wynosiła 8,4%.
Wnioski Uzyskanie wyniki wskazują, że maleinian
amlodypiny i benzenosulfonian amlodypiny stoso-
wane w monoterapii u chorych z łagodnym i umiar-
kowanym nadciśnieniem tętniczym charakteryzują
się porównywalną wysoką skutecznością hipoten-
syjną i porównywalną częstością zdarzeń niepożą-
danych. Leczenie maleinianem amlodypiny przez
dalsze sześć miesięcy charakteryzowało się wysoką
skutecznością hipotensyjną i dobrą tolerancją.
słowa kluczowe: amlodypina, badanie wieloośrodkowe,
skuteczność hipotensyjna, działania niepożądane,
nadciśnienie tętnicze
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form of calcium antagonist was used in a branch of
the TOHMS trial (Treatment of Mild Hypertension
Study), which compared the efficacy of basic groups
of antihypertensive drugs [5]. Later, during the pro-
cess of marketing approval, amlodipine maleate was
replaced by amlodipine besylate, which has been,
until recently, the only amlodipine salt on the market.
Earlier phase I studies suggested an equal pharmaco-
kinetic profile of the two salt forms [6–8]. Amlodipine
maleate and besylate administered to healthy volunteers
were characterized by a long half-life (31–37 h) [6, 7].
A formulation with a maleate salt of amlodipine was
developed, based on the preposition of the equivalent
therapeutic features of amlodipine, regardless of the
salt form in which the active substance exists in the
formulation. However, changing the salt form of
a drug may alter substantially its chemical and biolo-
gical properties that underlie differences in their clini-
cal efficacy and safety [9]. However there is, as yet, no
reliable way of predicting exactly the effect of chan-
ging the salt form of an active drug will have on its
biological activity. The supposition that the same salt
form of two related parent compounds will behave in
exactly the same way may not be always correct [9].
The objective of our study was, therefore, to eva-
luate the antihypertensive efficacy and tolerability of
amlodipine maleate during a 9-month study inclu-
ding a 3-month equivalence assessment with the refe-
rence amlodipine salt and a 6-month open non-com-
parative extension to the equivalence part in order to
provide further information on clinical efficacy and
tolerability during prolonged treatment with amlodi-
pine maleate in hypertensive patients. The prelimina-
ry results of the 3-month equivalence assessment in
a per protocol study population have been already pu-
blished in Arterial Hypertension [10].
Material and methods
The study was conducted in 7 centers in Poland,
and was composed of two phases. The first phase
was randomized, double-blind and parallel, enrol-
ling 263 patients with mild and moderate essential
hypertension. This 3-month comparative phase was
followed by a second one, in which 220 eligible pa-
tients were proposed to continue with amlodipine
maleate in an open non-comparative fashion for ad-
ditional 6 months. Each patient received detailed in-
formation about the study and signed an informed
consent form to participate before entering the trial.
The protocol of the study was in accordance with the
Declaration of Helsinki recommendations. The stu-
dy received approval from the local Ethics Commit-
Introduction
Calcium antagonists are the mainstay in the the-
rapy of hypertension, constituting a pharmacologi-
cally heterogeneous group. According to the 2003
guidelines of the European Society of Hypertension
and the European Society of Cardiology (ESH and
ESC) and as well as national Societies of Hyperten-
sion guidelines, calcium antagonists are among the
first choice of medication for mild and moderate hy-
pertension — along with diuretics, beta-blockers, an-
giotensin-converting enzyme (ACE) inhibitors, and
AT1 receptor antagonists [1, 2].
Amlodipine, a dihydropyridine derivative, is one
of the longest acting calcium antagonists; it is cha-
racterized by the slow onset of an antihypertensive
effect that lasts over 24 hours, a highly selective effect
on peripheral vessels and a favorable influence on
coronary circulation [3]. Due to the above mentio-
ned properties, it has become one of the most frequ-
ently prescribed calcium antagonists, both in mono-
therapy and combination, in more severe forms of
arterial hypertension [3, 4].
Amlodipine in the form of a maleate salt began
to be used in a clinical setting in the late 1980s and
early 1990s. It should be stressed that this particular
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tee. The study was audited by independent experts
in clinical studies.
The inclusion criteria in the first phase of the
study comprised male or female patients with essen-
tial hypertension defined as a sitting diastolic blood
pressure (DBP) being within the range of 95–
–114 mmHg and systolic blood pressure (SBP) be-
low 180 mm Hg. The study enrolled patients with
recently diagnosed, untreated hypertension or pa-
tients with hypertension having been diagnosed ear-
lier, in whom antihypertensive treatment had been
discontinued for at least a month before being inclu-
ded into the study. Patients were disqualified in ca-
ses of secondary or malignant hypertension, signifi-
cant cardiac, renal, hepatic or other serious diseases
that could have interfered with the study protocol.
Diabetics receiving insulin and pregnant, breast-fe-
eding women and women of reproductive age not
using contraceptives were also excluded from the trial.
The inclusion criteria for the prolonged follow-
-up period was adequate blood pressure control defi-
ned as reaching the target DBP of 89 mm Hg or at
least a 10 mm Hg reduction of DBP compared to the
baseline values (week 2).
The first phase started with a 2-week placebo
run-in period after which patients were randomly
assigned to receive amlodipine maleate or amlodipi-
ne besylate for 12 weeks. The starting dose of the
active treatment was 5 mg once daily. After 6 weeks
of treatment the dose was increased to 10 mg of am-
lodipine maleate or amlodipine besylate in patients
who failed to attain an adequate blood pressure re-
sponse, defined as the reduction of DBP below
90 mm Hg. The dosing schedule during the second
phase was similar to that during the first phase; during
the first three months, the patients received amlodipine
maleate in the maintenance dose they had had at the
end of the double blind phase. After three months the
dose was increased to 10 mg in patients with inadequate
blood pressure control. Patients who already received
the maximal dose of amlodipine were excluded from
the study due to the lack of efficacy. The structure and
the timeline of the study are displayed in Figure 1.
The medication applied in the first phase was
amlodipine maleate 5 mg tablets (Tenox®, Krka d. d.)
and the reference drug amlodipine besylate 5 mg ta-
blets (Norvasc®, Pfizer Inc.). The drugs were placed
into capsules of identical appearance. In the study,
capsules of 5 and 10 mg with evaluated and reference
drugs were used. During the second phase all pa-
tients received amlodipine maleate tablets 5 or
10 mg (Tenox®, Krka d. d.).
Patients were instructed to take the medication
early in the morning between 7 and 10 a.m. During
the active treatment period of the first phase patients
had check-ups with efficacy and safety evaluation
after 3, 6, 9 and 12 weeks. During the second phase
patients had one check-up after three months and
a final check-up after six months. The check-ups in-
cluded, apart from blood pressure and heart rate me-
asurements, a physical examination, and an asses-
sment of treatment tolerability. At the beginning of
RUN−IN PHASE DOUBLE BLIND, PARALLEL PHASE
Amlodipine maleate
5/10 mg
Amlodipine maleate
5/10 mg
Amlodipine maleate
5/10 mg
Amlodipine
maleate
5 mg
Amlodipine
besylate
5 mg
–2 0 6 12 weeks 3 6 months
Placebo
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Figure 1. Study structure
Rycina 1. Schemat badania
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the study the following tests were performed: elec-
trocardiography, ophtalmoscopy, blood cell count
and biochemical examinations (sodium, potassium,
calcium, creatinine, glucose, bilirubin, transaminase
and lipid levels). Electrocardiography was repeated
during the last check-up of each phase. Biochemical
parameters were assessed during each consecutive
check-up. Blood pressure was measured by a mercu-
ry sphygmomanometer (on the right arm, at sitting
position, measurements after 5 minutes rest, readings
were taken 3 times at 2 minutes intervals, 24 h after
taking the last dose of the medication).
The primary endpoint (primary efficacy varia-
ble) of the first phase was a comparison of the mean
absolute reduction of diastolic blood pressure in the
studied groups expressed as the difference between
diastolic blood pressure values measured during the
baseline visit at the beginning of the active treatment
(week 2) and at the end of the first phase (week 14).
The efficacy threshold was not determined in this
study. Instead, the margins of equivalence for the
primary efficacy variable were set at +4 mm Hg and
–4 mm Hg. In order to be claimed to be equivalent,
the mean value of the primary efficacy variable in the
group taking amlodipine maleate must not differ
from the mean value in the group taking amlodipine
besylate by 4 mm Hg or more.
The secondary efficacy variables of the study
were comparisons of the mean absolute reduction
levels of systolic blood pressure (SBP) and heart rate
(HR) between the groups, the percentage of patients
with blood pressure normalization and the number
of respondents. The normalization of blood pressure
was defined as a DBP reduction below 90 mm Hg
and respondents were those who did not reach the
target DBP, although DBP had been reduced by
10 mm Hg or more.
Efficacy variables during the second phase were
similar to those during the first phase. We compared
DBP, SBP and HR changes, the percentage of pa-
tient with normalization as well as the percentage of
respondents at the end of second phase with baseline
values and with values at the end of the first phase.
An assessment of treatment tolerability was con-
ducted, based on the analysis of adverse reactions re-
ported during visits that had occurred while taking the
medication. If there was a possible relation between
an adverse reaction and the medication, it was assu-
med that it could not be excluded. During the first
phase, we compared the safety profiles of amlodipine
maleate and amlodipine besylate by assessing the inci-
dences of drug-related adverse events, the number of
patients excluded from the study and changes in labo-
ratory parameters or electrocardiograms.
During the second phase we followed-up all the
safety variables of the first phase and compared opti-
cal fundi changes assessed at the end of second phase
and at the beginning of the study.
Data analysis
The SAS statistical package (version 8.1; SAS
Institute, USA) was used for the calculation of re-
sults. In the primary efficacy analysis of the equiva-
lence assessment between the drugs two one-sided
t test procedures were used, with the adjustment of
the final measurement in the Intention-To Treat
(ITT) population (all randomized patients with at
least one post- randomization measurement). The
endpoint value was the last recorded measurement.
Analysis of the per protocol (PP) population was
then performed to confirm the results of the ITT
analysis. The PP population was defined as patients
who had completed the first phase within the plan-
ned time and study visits schedule with a complian-
ce of > 80% and no major protocol deviations. Re-
garding the equivalence margins for the 90% confi-
dence interval of ±4 mm Hg it was calculated that
114 patients were required per group to ensure the
study power of ≥ 80%. In the secondary efficacy ana-
lysis a two-sided t test was used for quantitative varia-
bles and Pearson’s Chi-squared test for categorical va-
riables. In the descriptive statistics, the mean and stan-
dard deviation was presented for quantitative
variables. The frequencies and percentages of the
patients were presented by the treatment group for the
qualitative variables. Within each treatment group the
significance of the differences in DBP, SBP, and heart
rate were analysed using the paired t-test.
In the safety analysis, a comparison was made
using similar statistical methods for the correspon-
ding type of variables as for the efficacy analysis. The
results throughout are presented as mean ± stan-
dard deviation.
Results
Efficacy
Altogether, 263 patients were enrolled in the first phase.
Of the 263 patients 13 did not fulfill randomization crite-
ria, noncompliance to inclusion criteria, adverse events,
or because they did not appear at the following check-up
(lost to follow-up). The remaining 250 patients were ran-
domly assigned to two groups receiving the evaluated or
reference medication. Two hundred and twenty-six pa-
tients completed the first phase of the trial. 24 patients
were withdrawn from this part of the study (table I).
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Five patients were withdrawn (lost to follow-up)
before the first evaluation of efficacy. The remaining
245 patients constituted the ITT population. Out of
226 patients who concluded the study, 219 constituted
the PP population, while in 7 patients, violation of the
study protocol prevented their inclusion in the PP analysis.
Two hundred and twenty patients were deemed
eligible for participation in the second phase, while
6 patients were not included due to inadequate blo-
od pressure control. Two hundred and eight were
actually included, since twelve patients withdrew
their consent. One hundred and ninety-eight patients
completed the trial. Ten patients were withdrawn
during the second phase. We performed an ITT ana-
lysis of the second phase in 202 patients who had
had at least one clinical evaluation during the se-
cond phase. One hundred and five analysed patients
were given amlodipine maleate throughout the who-
le study, while 97 had previously been taking amlo-
dipine besylate. The distribution of patients in the
study is displayed in table I.
Baseline characteristics at randomization did not dif-
fer significantly between the treatment groups (table II).
One hundred and thirty-four (54.69%) patients had
been previously treated with at least one antihyper-
tensive agent: ACE inhibitors (40.09%), calcium an-
tagonists (24.57%), beta-blockers (10.78%), AT re-
ceptor antagonists (10.34%), diuretics (9.91%), al-
pha-blockers (0.86%) or others (3.45%).
A primary efficacy variable analysis of 245 pa-
tients (ITT) has shown equal efficacy of the two salts
in terms of the DBP reduction (table III). The diffe-
rence in DBP reduction between the groups was
1.27 mm Hg in favour of amlodipine besylate and
the 90% CI fell entirely within the equivalence mar-
gins. The PP results have confirmed the ITT analy-
sis (data not shown).
An analysis of secondary efficacy variables did
not reveal any differences between the two groups
(table IV). Both drugs significantly lowered DBP and
SBP after 12 weeks of treatment compared with the
Patients A. maleate A. besylate All
First phase
Enrolled — — 263
Randomized 125 125 250
Completed 114 112 226
Withdrawals: 11 13 24
— lost to follow up 5 1 6
— adverse events 3 2 5
— withdrawn consent 0 1 1
— protocol violation 3 9 12
Analysed (ITT) 121 124 245
Analysed (PP) 110 109 219
Second phase
Enrolled 208 — —
Completed 198 — —
Withdrawn: 10 — —
— lost to follow-up 7 — —
— adverse events 2 — —
— inadequate blood
   pressure control 1 — —
— protocol violation 1 — —
Analysed (ITT) 202 — —
Table I. Patients distribution
Tabela I. Rozkład chorych
A. maleate A. besylate
n = 125 n = 125
Age (years) 43.0 ± 12.4 43.7 ± 12.7
Male gender (%) 84.0 83.0
Body mass index [kg/m2] 26.8 ± 4.2 27.4 ± 3.9
SBP [mm Hg]1 154.3 ± 10.4 153.5 ± 9.8
DBP [mm Hg]1 101.4 ± 3.6 101.8 ± 3.7
HR [beats/min] 74.3 ± 7.0 74.7 ± 7.8
Previous antihypertensive
therapy (%) 53.7 55.7
p = NS for all the comparisons between the groups
1SBP and DBP values after two-weeks of placebo run-in period
Table II. Baseline characteristics of the randomized popu-
lation (n = 250)
Tabela II. Charakterystyka wyjściowa chorych (n=250)
Table III. Analysis of the primary efficacy variable
Tabela III. Ocena skuteczności leczenia — rozkurczowe
ciśnienie tętnicze
A. maleate A. besylate
N 121 124
DBP reduction [mm Hg]
mean ± SD –16.67 ± 6.80 –17.94 ± 6.10
Range od –31 do +5 od –40 do +2
p (equivalence margin =
= –4 mm Hg) < 0.001
p (equivalence margin =
= +4 mm Hg) 0.001
90% confidence
   interval [mm Hg] –0.35 + 2.90
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baseline values while HR was significantly not changed
in any of the groups. The percentage of patients whose
DBP was adequately controlled showed no significant
difference between the groups and the number of re-
spondents (patients who did not reach the target DBP
and whose DBP reduction was 10 mm Hg or more)
was too small to perform a relevant analysis of data.
The curves of blood pressure reduction during the first
phase were similar in both drugs (Fig. 2).
Altogether 129 patients (55.6%) in the ITT po-
pulation continued the therapy with a 5 mg dose
after 6 weeks of active treatment during the first pha-
se. Forty-nine patients (43%) treated with amlodipine
maleate and 54 (46%) patients treated with amlodipi-
ne besylate required an increase of the dose to 10 mg
after 6 weeks. This difference was not significant
(p = 0.67). The results of the PP analysis corrobora-
ted those of the ITT analysis. Since safety was a pri-
mary concern in the second phase, the efficacy ana-
lysis served only to assess the longer term blood pres-
sure control that could have been important for safe-
ty reasons.
The DBP/SBP reduction at the end of the second
phase was –17.5/–21.2 mm Hg compared to the base-
line values (paired t test, p < 0.0001). During the
second phase both the mean DBP and the mean SBP
were increased by 0.9 mm Hg in comparison with the
beginning of the second phase (paired t test,
p = 0.0062 and 0.043 for DBP and SBP, respectively).
Comparing these parameters in the group of patients
having received amlodipine maleate during the whole
trial with those who switched from amlodipine besy-
late to amlodipine maleate at the end of the first phase
there were no significant differences between the two
groups (table V). HR was not significantly changed at
the end of the second phase compared to the baseline
value, while it increased by 1.24 beats/min in compa-
rison with the beginning of the phase (p = 0.029).
Out of 202 patients analysed, 163 (80.7%) main-
tained the target DBP below 90 mm Hg at the end of
the second period. One patient was excluded due to
inadequate control of blood pressure representing
0.49% of the ITT population.
Safety
A comparative analysis of treatment tolerability
was performed on the ITT population of 245 patients.
During the first phase there were 129 adverse
reactions, i.e. adverse events probably or most proba-
bly related to the study drug, recorded in the study,
that occurred in 35 patients in the amlodipine male-
ate group and in 47 patients in the amlodipine besy-
late group (28.9% vs. 37.9%; p = NS). The most
common adverse reactions were: headache, lower
extremity edema, facial flushes and transaminase ac-
tivity elevations. The frequencies of adverse reactions
did not differ significantly between the treatment
groups (table VI). Most of the adverse reactions were
mild or moderate pronounced and occurred during
the first six weeks of treatment. Adverse reactions led
to the discontinuation of therapy in 3 patients (2.4%)
A. maleate A. besylate p
(n = 121) (n = 124) for the comparison
between the drugs
SBP reduction [mm Hg] –20.60 ± 12.6* –20.39 ± 12.94* 0.9403
HR change [beats/min] –0.89 ± 9.10 –0.51 ± 9.49 0.7466
BP normalisation (% pts) 90.91 89.52 0.7138
*p < 0.0001 compared to baseline
Table IV. A comparison of secondary efficacy variables between the groups
Tabela IV. Ocena skuteczności leczenia — skurczowe ciśnienie tętnicze i częstość
akcji serca
Figure 2. Changes in SBP and DBP during the active treatment
period of the first phase
Rycina 2. Zmiany w wysokości skurczowego (SBP) i rozkurczowe-
go (DBP) ciśnienia tętniczego w trakcie pierwszej części badania
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in the group receiving amlodipine maleate and in
2 patients (1.6%) in the group receiving amlodipine
besylate. Some of the patients had several complaints
listed in the Table IV.
During the second phase, out of 202 patients tre-
ated with amlodipine maleate, 17 patients had 19
adverse reactions, yielding an overall incidence of
8.4%. Thirteen adverse reactions were mild in inten-
sity, 5 adverse reactions were moderate and one ad-
verse reaction was severe. The most common adver-
se reactions were peripheral edema (4.5% of patients)
and increased ALT (2.5%) and increased AST (1%).
There were two patients excluded due to adverse re-
actions. An analysis of ECG did not show any diffe-
rences in ECG abnormalities at the end of each pha-
se compared to the baseline examination.
Discussion
Amlodipine, a dihydropyridine derivative, a third
generation calcium channel blocker, has the properties
that enable the smooth and gradual onset of its anti-
hypertensive effects, the prolonged duration of
these effects [11]. High efficacy and good tolerability
of amlodipine have been demonstrated in numerous
clinical trials. Amlodipine has been studied in many
large, multicentre clinical studies including TOHMS
[5], Antihypertensive and Lipid-Lowering Treat-
ment to Prevent Heart Attack Trial (ALLHAT) and
the recently completed Valsartan Antihypertensive
Long-term Use Evaluation [12, 13]. In these studies
two different salts of amlodipine were administered
— amlodipine besylate and amlodipine maleate. The
amlodipine maleate was assessed in the TOMHS stu-
dy while in other trials amlodipine besylate was used.
The TOMHS study, the only large long-term
study in which amlodipine maleate has been used,
included over 900 patients with essential mild hyper-
tension during a 4 year observation. It evaluated an-
tihypertensive action, tolerability and influence on
target organ damage and the metabolic profile of the
representatives of five basic groups of antihypertensi-
ve drugs: diuretic, beta-blocker, alpha-blocker, cal-
cium antagonist and converting enzyme inhibitor,
represented respectively by chlorthalidone, acebuto-
lol, doxazosine, amlodipine and enalapril. The
TOMHS study demonstrated the adequate antihy-
pertensive efficacy of amlodipine maleate, the favo-
rable influence of its lipids profile and the highest
proportion of patients (83%) receiving 5 mg of the
medication once daily, who continued the treatment
with the evaluated calcium antagonist [5].
Recently, amlodipine maleate was introduced
for the clinical use and is expected to have identical
pharmacological and clinical properties as amlodipi-
ne besylate. The main issues involving the problem
Adverse reaction A. maleate A. besylate Total
n = 121 n = 124 n = 245
Headache 11 (9.1) 16 (12.9) 27 (11.0)
Peripheral edema 10 (8.3) 8 (6.5) 18 (7.3)
Flushing 7 (5.8) 8 (6.5) 15 (6.1)
Increased ALT 8 (6.6) 10 (8.1) 18 (7.3)
Increased AST 5 (4.1) 7 (5.6) 12 (4.9)
Palpitation 2 (1.6) 4 (3.2) 6 (2.4)
Skin rash 2 (1.6) 4 (3.2) 6 (2.4)
Fatigue 1 (0.8) 2 (1.6) 3 (1.2)
Tachycardia 0 (0.0) 3 (2.4) 3 (1.2)
Constipation 2 (1.6) 0 (0.0) 2 (0.8)
Dizziness 2 (1.6) 0 (0.0) 2 (0.8)
The table contains number and percentage (in brackets) of patients with adverse reactions;
p = NS for all the comparisons between the groups
Table VI. Adverse reactions during the first phase
Tabela VI. Zdarzenia niepożądane w trakcie pierwszej
części badania
A. maleate — A. maleate A. besylate — A. maleate p
(n = 105) (n = 97) for the comparison between the drugs
DBP reduction [mm Hg]+ –17.4 ± 6.3 –17.5 ± 6.1 0.9099
SBP reduction [mm Hg]+ –21.4 ± 11.5 –20.9 ± 12.2 0.7320
DBP change [mm Hg]++ 0.77 ± 5.21 1.07 ± 4.12 0.6513
SBP change [mm Hg]++ 0.69 ± 6.23 1.04 ± 5.72 0.6513
+ Reduction at the end of the second phase with regard to the baseline values
++Change at the end of the second phase compared to the beginning of the second phase
Table V. Blood pressure changes in the second phase
Tabela V. Zmiany w wysokości ciśnienia tętniczego w trakcie drugiej części badania
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of the salt switch are the possible difference in phar-
macokinetic properties, including differences in so-
lubility and permeability, i.e. absorption of the active
substance, and safety issues due to presumably diffe-
rent toxicological profile of the two salts. Ideally,
pharmacological and toxicological activities of a gi-
ven drug should not be influenced by the selection of
a particular salt type used, however differences may
appear in some cases [14]. We have tested the phar-
macokinetic properties of the both salts in a bioequ-
ivalence study and have proven the same profile of
blood concentration, i.e. the rate and extent of ab-
sorption of both drugs (data on file). The preclinical
toxicological tests did not show any significant diffe-
rences between the two salts [15–18].
The results of our study have shown the equiva-
lent efficacy of both salts. The equivalence margin,
based on DBP, has been stated to be somewhat nar-
rower than in similar equivalence studies [19, 20] in
order to assure a reliable criterion for the equivalen-
ce of the antihypertensive effect. The study was desi-
gned to simulate normal clinical practice by titrating
the doses of study medication according to the blood
pressure response and by performing an ITT analy-
sis of the data. The results were also confirmed by
the previously published PP analysis [10], which in-
creases the reliability of claims regarding equivalen-
ce. The SBP data, heart rate and percentage of pa-
tients who reached the target blood pressure after 12
weeks of active therapy further supported the thera-
peutic equivalence of the two amlodipine salts. The
size of the therapeutic effect was not substantially
different from the other amlodipine studies with si-
milar dosing regimens [20–22].
The antihypertensive efficacy of amlodipine ma-
leate was maintained during the extended follow-up
phase, proving the absence of therapeutic escape.
The blood pressure reduction at the end of the nine-
-month follow-up was adequate and significant com-
pared to the baseline values. Blood pressure reduc-
tion, a minor increase of DBP and SBP at the end of
the study in comparison with the beginning of the
extended follow-up (second phase) and the percen-
tage of patients in whom blood pressure was adequ-
ately controlled were all comparable with other stu-
dies of a similar design [23]. The absence of a signi-
ficant difference in a minute increase in blood pres-
sure at the end of the 9 month follow-up between the
patients who had been receiving amlodpine maleate
throughout the entire trial and those who had swit-
ched from amlodipine besylate to amlodipine male-
ate after the first phase, strongly suggests that
a switch from amlodipine besylate to the maleate salt
of amlodipine does not result in any clinically signi-
ficant changes in blood pressure control. For these
results to be confirmed they would have to be com-
pared with data on patients who would have rece-
ived amlodipine besylate during the whole study,
which is beyond the scope of this trial.
The safety profiles of the two salts were compa-
rable with no significant differences in the parame-
ters investigated, including overall incidence of ad-
verse events, incidences of individual adverse events
and the number of patients excluded due to adverse
events. In general, the safety profile of study drugs in
this study was similar to the profile described in the
literature [20, 21, 24]. Our study showed the relative-
ly high incidence of AST and ALT slight increase in
both treatment groups, however the initial activity of
the liver enzymes had already been increased in
a substantial proportion of patients with abnormal
values at the end of the first phase. There were no
differences in the proportion of patients with abnor-
mal activity ALT or/and AST at the end of first pha-
se, compared with the initial check-up, as assessed
by the particular statistical methodology [25].
The incidence of drug-related adverse events
with amlodipine maleate during the extended fol-
low-up was much lower than in the first three mon-
ths of the study, indicating the stabilization of the
patient’s tolerance to the drug. The latter, together
with low number of patient exclusions due to adver-
se events, corroborate the satisfactory safety results of
the first phase and indicate that amlodipine maleate
is a well-tolerated and safe drug.
In conclusion, our study has shown the equiva-
lent efficacy and comparable safety profiles of two
amlodipine salts, which indicates that a different salt
form of the active substance amlodipine does not
have any clinical implications with respect the an
altered antihypertensive effect or a difference in the
safety profile. The extended follow-up period confir-
med the adequate blood pressure control and satis-
factory safety profile of amlodipine maleate.
Summary
Background A nine-month follow-up, multicenter study
was carried out to assess the efficacy and safety of
amlodipine maleate, a recently launched amlodipine salt
in 263 patients with essential hypertension.
Material and methods In the first phase of the trial,
a 3-month equivalence assessment with the reference
besylate salt has been carried out in a randomised double-
blind fashion including placebo run-in period. The equiva-
lence margins were set to be ± 4 mm Hg. The second
nadciśnienie tętnicze rok 2005, tom 9, nr 5
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phase was a 6-month open non-comparative extension of
the equivalence phase to provide additional information on
clinical efficacy and acceptability during prolonged treat-
ment with amlodipine maleate. Essential hypertension was
defined as a sitting diastolic blood pressure (DBP) being
within the range of 95–114 mm Hg and systolic blood pres-
sure below 180 mm Hg. An adequate blood pressure control
defined as reaching the target DBP of 89 mm Hg or at least
10 mm Hg reduction of DBP compared to the baseline val-
ues, was the inclusion criterion for the second phase. The
primary endpoint was the mean absolute reduction of DBP
at the end of the active treatment in relation to the baseline.
Results Altogether, 245 patients were analyzed in the
equivalence comparative part, while 202 patients were in-
cluded in the analysis of the open follow-up period. Both
drugs have significantly lowered DBP and SBP after
3 months of treatment compared with the baseline values
while heart rate has not been significantly changed in any
of the treatment groups. The difference in these param-
eters between the salts was not significant. The difference
in DBP reduction between the treatments was 1.27 mm
Hg in favour of the besylate salt and the 90% confidence
interval fell entirely within the equivalence margins.
There was no difference between the salts in the percent-
age of patients reaching the target DBP (90.91% and
89.52% for maleate and besylate, respectively). The DBP/
/SBP reduction after the amlodipine maleate at the end of
the 6-month second phase was –17.5/–21.2 mm Hg com-
pared to the baseline values (paired t test, p < 0.0001). Blood
pressure control was adequate during the second phase.
Thirty-five patients in the amlodipine maleate group and
47 patients in the amlodipine besylate group reported ad-
verse reactions during the 3-month comparative (28.9%
and 37.9%, for maleate and besylate, respectively, p = NS).
The overall incidence of amlodipine maleate-related ad-
verse events during the second phase was 8.4%.
Conclusions In conclusion, amlodipine maleate was shown
to be equivalent to the reference besylate salt in terms of
antihypertensive efficacy, and safety profiles of the two salts
were not significantly different. Amlodipine maleate ena-
bled adequate blood pressure control and was shown to be
well tolerated during the entire 9-month follow-up.
key words: amlodipine, multicenter study, antihypertensive
efficacy, side effects, essential hypertension
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